On 18 September 2024, NMIN spin-off company NanoVation Therapeutics (NTx) announced its entry into a multi-target partnership with Denmark-based global healthcare company Novo Nordisk.
The multi-year partnership aims to advance the development of novel genetic medicines targeting cardiometabolic and rare diseases. The approach will combine NTx’ proprietary long-circulating lipid nanoparticle (LNP) technology for extrahepatic RNA delivery with Novo Nordisk’s expertise in cardiometabolic and rare disease R&D and clinical translation.
By the terms of the partnership, Novo Nordisk will receive an exclusive license to NTx’s technology, and NTx will receive research funding and up to ~US$600 million in cash and potential milestone payments.
“This agreement… is validation of the potential of our LNP technologies to enable the next generation of life-changing genetic medicines,” said Dr. Dominik Witzigmann, co-founder and CEO of NTx, in the company’s corporate announcement.
“We are very excited to collaborate with the team at Novo Nordisk.”
“We in NMIN are thrilled but not surprised by the news of this top-tier partnership with one of the Network’s earliest spin-offs,” comments NMIN Executive Director Diana Royce.
“The revolutionary potential of NanoVation’s technology, in which they are world leaders, make such developments inevitable. We look forward to witnessing the great gains to be had from this collaboration, and we congratulate our NanoVation colleagues and friends.”
NanoVation Therapeutics is a pioneer in the design and creation of LNPs for nucleic acid delivery. NTx partners with leading pharmaceutical and biotech companies to enable the development of genetic medicines for previously untreatable diseases. Spun out from NMIN’s NanoCore Facility, NTx was co-founded and is led by former NMIN HQP Drs Dominik Witzigmann and Jayesh Kulkarni, together with a world-leading team of experts including NMIN Founding Scientific Director Dr. Pieter Cullis and other NMIN Network investigators.